# AUTHOR QUERY FORM

| | | |
|---|---|---|
| ELSEVIER | **Journal:** MAT | **Please e-mail or fax your responses and any corrections to:** |
| | | **E-mail:** corrections.eseo@elsevier.thomsondigital.com |
| | **Article Number:** 6298 | **Fax:** +353 6170 9272 |

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the 'Q' link to go to the location in the proof.

| Location in article | Query / Remark: **click on the Q link to go**<br>**Please insert your reply or correction at the corresponding line in the proof** |
|---|---|
| Q1 | Please confirm that given names and surnames have been identified correctly. |
| Q2 | Please check all author names and affiliations. |
| Q3 | Please check the hierarchy of the section headings for correctness. |
| Q4 | "Your article is registered as a regular item and is being processed for inclusion in a regular issue of the journal. If this is NOT correct and your article belongs to a Special Issue/Collection please contact c.field@elsevier.com immediately prior to returning your corrections.". |
| Q5 | Please note that Fig. 1 was not cited in the text. Please check that the citation as suggested by the copyeditor is in the appropriate place, and correct if necessary. |
| Q6 | Please check that the (a) Contributors; (b) Competing Interest and (c) Funding information appears at the end of your article and is correct. Thank you. |
| Q7 | Please check that the (a) Contributors; (b) Competing Interest and (c) Funding information appears at the end of your article and is correct. Thank you. |
| Q8 | One or more sponsor names and the sponsor country identifier may have been edited to a standard format that enables better searching and identification of your article. Please check and correct if necessary. |
| Q9 | Please check this section for correctness. |
| Q10 | Please provide the volume number and page range for the bibliography in Ref. [81]. |
| Q11 | Please confirm whether the first name and surname have been identified correctly for all the authors. |

| |
|---|
| Please check this box or indicate your approval if you have no corrections to make to the PDF file |

Thank you for your assistance.

# ARTICLE IN PRESS

## Graphical Abstract

**Chondrosenescence: Definition, hallmarks and potential role in the pathogenesis of osteoarthritis**

Ali Mobasheri*, Csaba Matta, Róza Zákány, Giuseppe Musumeci

## Highlights

*Maturitas xxx (2014) xxx–xxx*

### Chondrosenescence: Definition, hallmarks and potential role in the pathogenesis of osteoarthritis

Ali Mobasheri*, Csaba Matta, Róza Zákány, Giuseppe Musumeci

- Aging and inflammation contribute to the development and progression of arthritic and musculoskeletal diseases.
- "Inflammaging" refers to low-grade inflammation that occurs during physiological aging.
- "Chondrosenescence" refers to the age-dependent deterioration of chondrocyte function and is intimately linked with inflammaging.
- A better understanding of chondrosenescence may lead to the development of new therapeutic and preventive strategies for osteoarthritis.

Review

# Chondrosenescence: Definition, hallmarks and potential role in the pathogenesis of osteoarthritis

Q1 Ali Mobasheri[a,b,c,*], Csaba Matta[a,d], Róza Zákány[d], Giuseppe Musumeci[e]

[a] The D-BOARD European Consortium for Biomarker Discovery School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey,
Q2 Duke of Kent Building, Guildford GU2 7XH, Surrey, United Kingdom
[b] Center of Excellence in Genomic Medicine Research (CEGMR), King Fahd Medical Research Center (KFMRC), King AbdulAziz University, Jeddah 21589, Saudi Arabia
[c] Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, Arthritis Research UK Pain Centre, Medical Research Council and Arthritis Research UK Centre for Musculoskeletal Ageing Research, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom
[d] Department of Anatomy, Histology and Embryology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, H-4032 Debrecen, Hungary
[e] Department of Bio-medical Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, Via S. Sofia, 87-95125 Catania, Italy

## ABSTRACT

Aging and inflammation are major contributing factors to the development and progression of arthritic and musculoskeletal diseases. "Inflammaging" refers to low-grade inflammation that occurs during physiological aging. In this paper we review the published literature on cartilage aging and propose the term "chondrosenescence" to define the age-dependent deterioration of chondrocyte function and how it undermines cartilage function in osteoarthritis. We propose the concept that a small number of senescent chondrocytes may be able to take advantage of the inflammatory tissue microenvironment and the inflammaging and immunosenescence that is concurrently occurring in the arthritic joint, further contributing to the age-related degradation of articular cartilage, subchondral bone, synovium and other tissues. In this new framework "chondrosenescence" is intimately linked with inflammaging and the disturbed interplay between autophagy and inflammasomes, thus contributing to the age-related increase in the prevalence of osteoarthritis and a decrease in the efficacy of articular cartilage repair. A better understanding of the basic mechanisms underlying chondrosenescence and its modification by drugs, weight loss, improved nutrition and physical exercise could lead to the development of new therapeutic and preventive strategies for osteoarthritis and a range of other age-related inflammatory joint diseases. Aging is inevitable but age-related diseases may be modifiable.

© 2014 Published by Elsevier Ireland Ltd.

## Contents

* Corresponding author at: The D-BOARD European Consortium for Biomarker Discovery, School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of Surrey, Duke of Kent Building, Guildford GU2 7XH, Surrey, United Kingdom. Tel.: +44 7790824544; fax: +44 1483 686757.
E-mail addresses: ali.mobasheri.manuscripts@gmail.com, a.mobasheri@surrey.ac.uk (A. Mobasheri).

## 1. Introduction

Aging is a natural and inevitable process by which living organisms approach the twilight of their existence. Human aging is a complex physiological process, which is accompanied by the gradual decline and adaptation of different body systems to the unavoidable passage of time. It is characterized by a progressive loss of structure, function, co-ordination and physiological integrity, leading to impaired homeostasis in all systems [1]. Aging is a risk factor for a variety of chronic health problems including cancer, diabetes, cardiovascular and neurodegenerative disorders. Advancing age is also a risk factor for arthritic and musculoskeletal diseases. There are common factors or "hallmarks" associated with each of these diseases. For example, there are six hallmarks associated with cancer (see [2,3]). Aging itself is characterized by nine hallmarks [1]. These include genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Current research is attempting to examine the relative contributions of the hallmarks of aging and the links between them in order to identify pathways and targets that can be exploited to promote healthy aging and develop new, more effective and more targeted drugs and treatments with minimal side effects for diseases known to be associated with aging (Fig. 1).

One of the hallmarks of aging is cellular senescence. Normal cells possess a finite lifespan. Cells are continually exposed to a variety of harmful exogenous and endogenous factors that may induce stress and cause reversible or irreversible damage leading to complete recovery or cell death, respectively [4]. Unlike cancer cells, normal cells do not divide indefinitely due to a process known as cellular or replicative senescence [5]. Cellular senescence was formally described by Hayflick more than 50 years ago as a process that limited the growth and proliferation of normal human cells in culture [6]. Therefore, in cultured cells in vitro, replicative senescence limits the proliferation of normal cells, causing them to irreversibly arrest growth and adopt striking changes in cell form and function [7]. However, in vivo in aging adult tissues, senescent cells simply accumulate within tissues. Replicative senescence may contribute to ageing but it has been proposed that this process evolved to protect higher eukaryotes, particularly mammals, from developing cancer [8]. However, paradoxically, in older organisms, senescent cells may have the undesired effect of contributing to age-related pathologies and may actually contribute to carcinogenesis [9]. Cellular senescence is an important mechanism for preventing the proliferation of potential cancer cells and it is increasingly recognized as a critical feature of mammalian cells to suppress tumorigenesis, acting alongside cell death programs [5,10].

Mammalian organisms contain two types of cells: post-mitotic cells, which never divide, and mitotic cells, which have the capacity to divide. Examples of post-mitotic cells include nerve, muscle, and fat cells, most of which persist for life. Mitotic cells include epithelial and stromal cells of organs such as the skin. Post-mitotic and mitotic cells differ in their proliferative capacity, and thus they may age by different mechanisms [11]. Skin is an organ that clearly shows the signs of aging. Senescent keratinocytes and fibroblasts accumulate with age in human skin. Senescent skin cells possess a unique phenotype and exert long-range, pleiotropic effects [11]. They express a distinctive set of degradative enzymes, growth factors and pro-inflammatory cytokines [11]. Therefore, a few senescent cells in tissues such as skin might be able to compromise its function and integrity. The same principle may apply to several other tissues where a small number of senescent cells may interfere with the physiological functions of that tissue.

In this paper we review the published literature that support the concept of "chondrocyte senescence" may have similar effects in aging articular cartilage. We propose the term "chondrosenescence", define it as the age-dependent deterioration of chondrocytes and highlight its hallmarks and how they affect the phenotype of these cells and their specialized functions. We also propose the concept that a small number of senescent chondrocytes may be able to take advantage of the inflammatory tissue microenvironment and the inflammaging and immunosenescence that is concurrently occurring in the arthritis patient, further contributing to the age-related degradation of articular cartilage and other joint tissues. In this new framework chondrosenescence is intimately linked with inflammaging and the disturbed interplay between autophagy and inflammasomes [12]. This refined definition contextualizes the pro-inflammatory phenotype of chondrosenescent cells during the aging process and in age-related joint diseases, implicating mitochondrial dysfunction [13,14], oxidative stress and activation of inflammasomes [15]. The release of soluble and insoluble factors secreted by senescent chondrocytes further contributes to the inflammatory microenvironment that is believed to drive the catabolic degradation of extracellular matrix (ECM) macromolecules in articular cartilage. Since these molecules may be viewed as biochemical markers (biomarkers) of chondrosenescence, we also provide a brief overview of markers that may be used to identify and characterize chondrocytes in vitro and in vivo.

## 2. Aging and inflammation—"Inflammaging"

"Inflammaging" is defined as "low-grade chronic systemic inflammation established during physiological aging" [16]. The aging phenotype, is characterized by immunosenescence, and is explained by an imbalance between inflammatory and anti-inflammatory pathways, which results in a "low grade chronic pro-inflammatory status" [17]. Inflammaging is thought to be driving force behind many forms of age-related pathologies, such as neurodegeneration, atherosclerosis, metabolic syndrome, diabetes mellitus and sarcopenia [16]. There is also increasing evidence to suggest that inflammaging is also associated with inflammatory diseases of the musculoskeletal system (i.e. osteoporosis, osteoarthritis and rheumatoid arthritis) [18–20]. In this context, humans and animals must maintain homeostasis as they age despite incessant attack from both intrinsic and extrinsic stimuli [21]. Increased longevity results in a reduced capacity to mount inflammatory responses to infections and coordinate efficient anti-inflammatory responses to antigens and other noxious agents in

**Cellular Factors:**
Apoptosis, secondary necrosis, hypocellularity
Mitochondrial and autophagic dysfunction
Catabolic factors:
  Pro-inflammatory cytokines, chemokines, adipokines
  Reactive oxygen species (ROS)
  Nitric oxide (NO)
  NF-κB
  Prostaglandins, leukotrienes, bioactive lipids
  Toll-like receptor (TLR)/Receptor for advanced glycation end products (RAGE) activation
  Matrix metalloproteinases, aggrecanases, cathepsins

**Systemic and OA Risk Factors:**
Age
Obesity, overweight and sedentary lifestyle
Mechanical factors
  Joint trauma, joint instability, joint overuse, increased joint laxity - increased stiffness of periarticular ligaments and tendons
Anatomic factors, joint shape and conformation
Genetics, epigenetics
Metabolic disease
  Diabetes mellitus – formation of advanced glycation end-products (AGEs), oxidative stress
Endocrine disease

**Synovial Factors:**
Synovitis

**Adipose Tissue Factors:**
Increased adiposity

**Bone Factors:**
Bone marrow lesions

**Chondrosenescence**: the age-dependent deterioration of chondrocytes as a consequence of replicative (intrinsic) and stress-induced (extrinsic) factors, resulting in the development of a "senescent secretory phenotype"

**Musculoskeletal and CNS Factors:**
Sarcopenia and muscle weakness
Loss of proprioception and balance

**Related Musculoskeletal Conditions:**
Osteoporosis?
Previous rheumatoid arthritis?
Previous septic arthritis?
Other musculoskeletal co-morbidities?

**Cellular Alterations:**
Loss of phenotype and differentiated functions
Changes in chondrocyte metabolic activity
Increased sensitivity to pro-inflammatory and catabolic factors
Decreased responsiveness to anabolic growth factors
Impaired repair mechanisms
Development of a "senescent secretory phenotype"

**Systemic Alterations:**
Chronic pain
Sleep disturbance
Increased disability
Loss of mobility
Increased morbidity

**Joint Tissue Alterations:**
Crepitus and cardinal signs of joint inflammation
Compromised tissue structure and function
Vascular invasion (angiogenesis), increased neurogenesis and altered nociception
Loss and degradation of extracellular matrix macromolecules
Consequent changes in subchondral bone and synovium

**Fig. 1.** *The hallmarks of chondrosenescence.* Chondrosenescence is defined as the age-dependent deterioration of chondrocytes as a consequence of replicative (intrinsic) and stress-induced (extrinsic) factors, resulting in the development of a "senescent secretory phenotype". The intrinsic and extrinsic factors involved are listed.

our food and environment. Molecular evidence points to a disturbed interplay between autophagy and inflammasomes [12]. Declined autophagic capacity in aging cells impairs the process of cellular housekeeping. This leads to protein aggregation, accumulation of misfolded proteins and the formation of dysfunctional mitochondria, which increases the generation of reactive oxygen species (ROS) thus promoting oxidative stress. Recent studies indicate that oxidative stress can induce the assembly of multiprotein inflammatory complexes called the inflammasomes [15]. Nod-like receptor protein 3 (NLRP3) is the major immune sensor for cellular stress signals. NLRP3 inflammasome-dependent inflammatory responses are triggered by a variety of signals of host danger, including infection, tissue damage and metabolic dysregulation [13,14]. Inflammatory signals activate inflammasome-dependent responses and caspases, predominantly caspase-1, which cleaves the inactive precursors of interleukins, thus stimulating their elevated secretion and activity [12]. Consequently, these cytokines provoke inflammatory responses and accelerate the aging process by inhibiting autophagy, which is believed to be a protective mechanism in cartilage. Autophagy may be a protective or homeostatic mechanism in normal cartilage [22]. However, in OA it is associated with a reduction and loss of Unc-51-like kinase 1 (ULK1), an inducer of autophagy, Beclin1, a regulator of autophagy, and microtubule-associated protein 1 light chain 3 (LC3), which executes autophagy and a increased chondrocyte apoptosis (see subsequent sections) [23].

## 3. The inflammatory microenvironment of chondrocytes

Chondrocytes exist in an avascular microenvironment, with low nutrient and oxygen levels [24,25]. Although chondrocytes rely on glycolysis [26], some of the metabolic functions of these cells are oxygen dependent [27,28]. Oxygen is mainly supplied by diffusion from the synovial fluid [24,29]. Consequently, the lack of oxygen means that chondrocytes display a metabolism adapted to anaerobic conditions [27,28,30]. There is little published information about the regulation of antioxidant enzymes within cartilage.

Equally little is known about the transport of antioxidants from the circulation to chondrocytes. However, transport of nutrients, oxygen and antioxidants to chondrocytes is thought to occur by diffusion from subchondral bone [31] and the synovial microcirculation [32]. The role of subchondral bone in the pathogenesis of cartilage damage has been underestimated [31]. There is increasing evidence that vascular pathology plays a role in the initiation and/or progression of OA [33]. In pathological conditions, oxygen tension in synovial fluid is subject to fluctuation as blood flow may be reduced by venous occlusion and stasis, vascular shunt and fibrosis in synovium and/or by the development of microemboli in the subchondral vessels [33]. In response to oxygen variations induced through ischemia/reperfusion injury, mechanical stress, immunomodulatory and inflammatory mediators, chondrocytes produce abnormal levels of reactive oxygen species (ROS) that are generally produced by immune cells [27,28,34]. The main ROS produced by chondrocytes are NO and superoxide anion that generate derivative radicals, including peroxynitrite and hydrogen peroxide ($H_2O_2$) [35,36]. NO and its redox derivatives appear to have a number of different functions in both normal and pathophysiological joint conditions [37]. Low NO concentrations have protective effects on other cell types and the literature that deals with this area is beyond the scope of this review. Chondrocytes stimulated with pro-inflammatory cytokines produce large amounts of NO, which has been implicated in OA and has the capacity to inhibit extracellular matrix production by interfering with important autocrine and paracrine factors [38]. The published literature suggests important roles for NO in inflammation and pain associated with OA but this area is highly controversial and more work needs to be done to clarify the role of NO in joint health and disease [39]. NO is synthesized by nitric oxide synthase (NOS) enzymes. Chondrocytes express both endothelial (eNOS) and inducible (iNOS) forms of the enzyme. NO production is stimulated by cytokines (*i.e.* IL-1β, TNF-α), interferons (*i.e.* interferon γ (IFN-γ) and lipopolysaccharides (LPS). In fact the increased expression of iNOS and cyclo-oxygenase-2 (COX-2) in OA is largely due to the increased expression of pro-inflammatory cytokines, particularly IL-1β, which act in an autocrine/paracrine

fashion to perpetuate a catabolic state that leads to progressive destruction of articular cartilage [40]. In contrast NO production is inhibited by growth factors such as transforming growth factor β (TGF-β).

In healthy cartilage chondrocytes possess robust defence mechanisms against attack by NO, free radicals and reactive oxygen species (ROS). However, responses to ROS generation will be dependent on redox status at the cellular level and influenced by systemic levels of inflammatory mediators, if present. When the oxidant level does not exceed the reducing capacities of cells, ROS are strongly involved in the control of cellular functions including signal transduction. In contrast, in some pathological situations, when the cellular antioxidant capacity is insufficient to detoxify ROS, oxidative stress may occur that degrade not only cellular membranes and nucleic acids but also extracellular components including proteoglycans and collagens. This is likely to happen in certain OA phenotypes. Furthermore, ROS can modify proteins by oxidation, nitrosylation, nitration or chlorination of specific amino acids, leading to impaired biological activity, changes in protein structure and accumulation of damaged proteins in the tissue.

A further point that needs to be made in connection with oxidative stress is the fact that redox sensitive transcription factors (*e.g.* NF-κB) are upregulated, which might result in an uncontrolled inflammatory response. Oxidative stress may also cause cell death and release of cellular content into extracellular environment, activating clearance mechanisms in the microenvironment. Altogether, degradation products and cellular content containing oxidized molecules may contribute to the exacerbation of synovial inflammation and form a vicious circle, constituted by newly formed ROS and further degradation products.

The enzyme complex NADPH, which catalyzes the reduction of molecular oxygen to superoxide anion radicals, produces superoxide anion radicals. Biochemical studies have shown that chondrocytes express the large subunit of the flavocytochrome of NADPH oxidase [41]. Even immortalized human chondrocyte-like cells lines express various components of the NADPH oxidase complex [42]. Articular chondrocytes also appear to express cell-specific components of NADPH oxidase complex such as p22phox, p40phox, p47phox, p67phox and gp91phox [41].

## 4. Hallmarks of chondrosenescence

There are common factors or "hallmarks" associated with every chronic disease. Six different hallmarks have been associated with cancer [2,3] and aging itself has at least nine hallmarks [1]. However, there are no published papers that have specific hallmarks listed as being associated with chondrosenescent cells in OA. However, before we list these hallmarks, it is appropriate to address this fundamental question: *what is the impact of cartilage aging?*

Clearly, age is one of the most important risk factors for OA, followed by obesity, joint trauma, joint instability, genetic factors, underlying metabolic or endocrine disease. However, as we age, our tissues undergo age-related changes. These include changes in metabolic activity, mitotic activity, decreased sensitivity of chondrocytes to growth factors (especially changes in chondrocyte transforming growth factor β (TGF-β) signalling [43]), decreased responsiveness to anabolic mechanical stimuli and impaired "repair mechanisms [44]. Age-related changes in articular cartilage can contribute to the development and progression of OA. However, the degeneration of normal articular cartilage "is not simply the result of aging and mechanical wear" [45]. Nevertheless, aging modifies the structure and function of articular cartilage and other joint tissues such as subchondral bone, muscle, soft tissues, synovial membrane, and synovial fluid. In aging articular cartilage chondrocytes exhibit an age-related decline in proliferative and synthetic capacity while maintaining the ability to produce pro-inflammatory mediators and matrix degrading enzymes [46]. These findings are characteristic of the senescent secretory phenotype and are most likely a consequence of extrinsic stress-induced senescence driven by oxidative stress rather than intrinsic replicative senescence. Extracellular matrix changes with aging also contribute to the propensity to develop OA and include the accumulation of proteins modified by non-enzymatic glycation.

## 5. The role of apoptosis in joint inflammation

Apoptosis, also known as programmed cell death (PCD) is the physiologically regulated process of dell death that occurs in multicellular organisms during embryonic development. Various definitions have been proposed for apoptosis [47,48] since the term was initially introduced by Kerr, Wyllie and Currie [49]. Research carried out over the last twenty-five years has demonstrated a clear role for apoptosis in a variety of chronic diseases including joint inflammation and arthritis. The demonstration of macrophage phagocytosis of aging neutrophils in joint inflammation was one of the first studies that linked apoptosis to arthritis [50]. Interestingly, the authors of this original study proposed that apoptosis in the synovial joint may represent a mechanism for the removal of neutrophils during inflammation, a process that may serve to limit the degree of joint injury during inflammation [50]. A few years later apoptosis was observed in the synovium in rheumatoid arthritis (RA) [51]. Firestein and colleagues studied RA synovial tissue (ST) to determine if and where apoptosis occurs *in situ*. They used immunohistochemical techniques to show that DNA strand breaks occur mainly in macrophages, although some fibroblast-like cells in the RA synovium were also labelled. They also proposed that pro-inflammatory cytokines regulate this process, and the cytokine profile in RA (high interleukin 1β (IL-1β), high tumour necrosis factor α (TNF-α) and low interferon γ (IFN-γ) along with local oxidant injury might conspire to favour induction of apoptosis in the synovium [51]. This was one of the first reports of "inflammaging" in the synovial joint, although this term was not specifically mentioned at this stage. Further evidence for apoptosis in RA was provided by ultrastructural studies that demonstrated Fas and Bcl-2 expression in synovial fibroblasts from patients with RA [52]. Fas is an important cell surface receptor belonging to the TNF receptor superfamily, also known as CD95, that induces apoptosis on binding Fas ligand and Bcl-2 is an integral outer mitochondrial membrane protein that blocks apoptosis and its increased abundance is a reflection of apoptotic activity in tissues. Therefore, observations of Fas antigen, Fas ligand and the tumour suppressor protein p53 over-expression in RA synovial tissue [53,54] and accumulation of soluble Fas ligand in serum and synovial fluid of patients with RA [55] added further molecular evidence for the involvement of apoptosis in joint inflammation and the accumulation of soluble Fas in the joint cavity of RA patients was proposed as a mechanism that may inhibit apoptosis and exacerbate the inflammatory process [55]. The expression of Bcl-2 is thought to result in extended life of matrix degrading synovial fibroblasts at the site of synovial invasion into cartilage and bone in RA joints [52]. Indeed, identification of apoptotic changes in osteocytes in pathological human bone indicated a functional role for apoptosis in remodelling in joint disease [56]. Increased synovial apoptosis and focally regulated endothelial proliferation in the synovium pointed to microvascular dysfunction as a mechanism for facilitating persistent synovitis in RA [57].

Transgenic mice lacking collagen II were found to exhibit increased apoptosis and led to the suggestion that apoptosis may also play a role in degenerative joint diseases such as OA in which there is extensive cartilage loss [58]. Hashimoto et al., studied

Fas/Fas ligand expression and induction of apoptosis in chondrocytes from normal and OA cartilage [59]. They found that subpopulations of chondrocytes express Fas and are susceptible to Fas-induced apoptosis and Fas-mediated chondrocyte loss may contribute to cartilage degradation in OA [59] and RA [60]. Blanco et al., used FACS analysis and the TUNEL technique to show that OA chondrocytes indeed die by apoptosis and proposed increased apoptosis as a possible pathogenic pathway for OA [61]. Linking chondrocyte apoptosis and cartilage degradation in OA suggested that apoptosis and extracellular matrix depletion in articular cartilage are anatomically linked and may be mechanistically related [62]. Taken together, these studies revealed that apoptotic chondrocyte death plays an important role in the pathogenesis of OA and could be targeted for the development of new therapeutic strategies. Further mechanistic insight came from clinical and laboratory animal studies from the Lotz group in La Jolla that demonstrated a role for nitric oxide (NO) or antibody to Fas undergo cell death by apoptosis [63] (reviewed in [64]). Another elegant study by the Lotz group revealed that apoptotic bodies isolated from NO-treated chondrocytes or cartilage contain alkaline phosphatase and NTP pyrophosphohydrolase activities and can precipitate calcium [65]. This was the first study that implicated chondrocyte-derived apoptotic bodies in the pathologic cartilage calcification seen in aging and OA.

According to the recent literature there is a significant decrease in chondrocyte abundance in articular cartilage with aging and a moderate to strong positive correlation exists between the degree of cartilage damage and chondrocyte death by apoptosis [66]. Although there is a strength relation between chondrocyte apoptosis and cartilage degeneration in human osteoarthritis (OA), in 40–60-year-old donors' cartilages there are unusually high numbers of apoptotic chondrocytes also in macroscopically normal cartilage [66].

## 6. Morphological features of chondrocyte apoptosis

Cells that undergo apoptosis exhibit a characteristic pattern of morphologic changes, including cell shrinkage, condensation, fragmentation of the nucleus and bubbling of the plasma membrane, known as "blebbing," and chromatin condensation and nucleosomal fragmentation [47]. These morphological features have been described in chondrocytes from murine models of OA [67] and in human OA samples [68]. Various methods have been published for evaluating them [69]. These features have also been described in hypertrophic chondrocytes in the growth plate [70] but the relevant literature is beyond the scope of this review. Some investigators have even proposed the term 'chondroptosis' to reflect the fact that chondrocytes may undergo apoptosis in a non-classical manner [71]. However, the term 'chondroptosis' has not been widely used or adopted. Freshly isolated chondrocytes from human OA cartilage exhibit morphological evidence of apoptosis, with clear cytoplasmic, cell-surface blebs, altered nuclear shape, apoptotic bodies and a parallel loss of nuclear volume [72].

## 7. Targeting apoptotic pathways in OA

Chondrocyte apoptosis is a challenging target for the development of therapeutic interventions for OA because of the potentially harmful systemic effects that pharmacological and biological regulators of apoptosis may have, especially the potential for development of tumours. However, the joint is more isolated from systemic regulation than many other organs. Therefore, the death receptor, mitochondrial and endoplasmic reticulum pathways and the major cellular pathways that regulate apoptosis could be targets of innovative new treatments. Of all the elements involved in the apoptosis of chondrocytes, caspase inhibition has been studied with the greatest detail (reviewed in [73]). However, caspases are not the only targets. There are other molecular targets with the capacity to modulate mitochondrial function and these have already been reviewed [73].

## 8. Age-related alterations in chondrocyte calcium signalling pathways

Calcium signalling is extraordinarily diverse and versatile, affecting almost all cellular functions including metabolism, proliferation, differentiation, and apoptosis [74]. While calcium homeostasis of differentiating and mature chondrocytes has been partially characterized [75], little is known about age-related changes of these pathways in senescent chondrocytes. It has long been established that alterations in $Ca^{2+}$ homeostasis, including mitochondrial $Ca^{2+}$ overload, are linked to aging [76]. For example, in senescent detrusor as well as cerebral arterial smooth muscle cells, calcium signals with decreased amplitudes but with increased durations were observed, reflecting on disturbances in both $Ca^{2+}$ influx (e.g. inhibition of voltage-operated calcium influx, increased calcium mobilization by ATP) and elimination pathways [77,78]. This suggests that alterations in $Ca^{2+}$ signalling can also be expected in ageing chondrocytes. A recent study that evaluated and compared gene expression profiles using microarrays in knee joint tissues from younger and older adult mice after experimentally induced OA, interesting alterations were found [79]. Among the genes with altered expression in older mice compared to younger animals, genes involved in $Ca^{2+}$ signalling were significantly represented. The genes that were downregulated in older mice included regulatory molecules: the histidine-rich calcium binding protein (Hrc), which is a regulator of ER calcium sequestration, and the versatile intracellular regulatory protein S100B; the ER calcium release channel RyR1; the alpha2/delta1 (CACNA2D1) and gamma6 (CACNG6) regulatory subunits of voltage-gated calcium channels; the sodium/calcium exchanger involved in calcium elimination pathways (NCX3); and a calcium-regulated ion transporter, the large conductance calcium-activated potassium channel ($K_{Ca}1.1$; KCNMA1). At the same time, several other subsets of genes involved in calcium homeostasis were found to be upregulated in older mice vs. younger animals, including ionotropic purinergic receptors $P2X_1$, $P2X_4$, $P2X_7$, and the transient receptor potential cation channel, subfamily C, members 1 and 6 (TRPC1, TRPC6). Disturbed calcium homeostasis in senescent chondrocytes is likely and increased expression of purinergic receptors in aged chondrocytes, similar to what has been observed in ageing myocytes, is of particular importance, considering the key role of these receptors in the calcium homeostasis of chondrocytes [80,81]. It is therefore clear that we are far from identifying biomarkers among the members of the calcium toolkit that would be reasonable indicators for chondrosenescence. However, the fact that there are alterations in the mRNA expression of molecules involved in calcium signalling implicates that research into this field may shed more light on the process of chondrosenescence.

## 9. Alterations in the chondrocyte channelome in aging chondrocytes

Ion channels that enable ion transport across the plasma membrane are vital components of cellular homeostasis. It is now evident that chondrocytes are characterized by an ever-expanding complement of ion channels referred to as the chondrocyte channelome [82]. The resting membrane potential (RMP), which is known to control the mRNA expression of cartilage matrix components [83] in chondrocytes, is maintained by plasma membrane

ion transporters. Since altered activity of $Na^+$ channels and ATP-sensitive $K^+$ ($K_{ATP}$) channel has been reported in other tissues in various aging models [84,85], it is also realistic to expect age-related changes in the chondrocyte channelome. Indeed, changes have already been observed in $K_{ATP}$ channel expression in OA chondrocytes and the function of $K_{ATP}$ channels appears to be impaired in OA chondrocytes [86] (see the following section for more details).

In the previously mentioned microarray study that compared gene expression profiles in knee joint tissues from younger and older mice [79], alterations in the expression of genes encoding ion channels and other transporters were detected. Most importantly, the $\alpha 2$ isoform of the $Na^+$, $K^+$-ATPase (*ATP1A2*) was reported to be downregulated in aged cartilage. Apart from VOCC subunits and $K_{Ca}1.1$, other transporter subunits including $Na_V b_4$ voltage-gated sodium channel, or $Na^+/Ca^{2+}$ exchanger 3 (NCX3) were also downregulated. In contrast, several transporters were upregulated in aged cartilage *vs.* younger controls, for example the ligand-gated purinergic receptors $P2X_1$, $P2X_4$, $P2X_7$, as well as TRPC1 and TRPC6. Furthermore, the cation transporter ATPase type 13A2 (*ATP13A2*) was also found to be affected [79]. It is important to note that these data only show that there are alterations of these molecules at the mRNA expression level; however, there are no data available regarding the protein level expression or function of these molecules.

Therefore, it is only possible to consider these molecules as potential biomarkers of chondrosenescence when protein expression and functional data become available.

### 9.1. The role of mitochondrial dysfunction, anaerobic metabolism and oxidative stress in chondrosenescence

Cellular senescence and mitochondrial dysfunction have both been listed among the nine tentative hallmarks of aging in different organisms [1]. In tissues where cells regularly replicate, gradual telomere shortening ultimately leads to definite arrest of cell cycle [87].

In articular cartilage, where chondrocytes, the only resident cell type of the tissue are quiescent and rarely, if ever, divide under physiological conditions replicative senescence would seem unlikely. Nonetheless, telomere shortening was detected in chondrocytes isolated from articular cartilage of older adults [88]. This "non-replicative" telomere erosion can be the result of various external and internal stressors such as continuous mechanical load or hypoxia. Articular chondrocytes are embedded into an avascular extracellular matrix and supplied by oxygen and nutrients from synovial fluid by slow diffusion. Although direct measurement of $O_2$ tension in articular cartilage is difficult, it does not exceed the $O_2$ level of synovial fluid, which has been estimated to be around 5–6% [89]. Metabolism of articular chondrocytes is well adapted to this hypoxia and elevation of oxygen content of their environment does not result in increased oxygen consumption [90]. The vital role of this unique oxygen homeostasis in development and maintenance of cartilage has been demonstrated by the observation that hypoxia-inducible factor-1(HIF-1) was indispensable for survival of chondrocytes [91]; whether the expression level of HIF-1 changes with ageing of chondrocytes has not been elucidated yet. Hypoxia-induced genes include glucose transporters (GLUT1, GLUT3), which are important for anaerobic metabolism [25,92,93]. Articular chondrocytes express multiple isoforms of these facilitative GLUTs and some have been shown to be regulated by growth factors and cytokines [25,93,94]. Although hypoxia, growth factors and cytokines are involved in regulating the overall glucose transport capacity of human chondrocytes, recent studies have shown that ATP-sensitive potassium [K(ATP)] channels are present in chondrocytes [95] and are involved in the regulation of GLUT1

and GLUT3 abundance in these cells. [86]. Therefore, K(ATP) channels are components of a broad glucose sensing apparatus that modulates glucose transporters and allows chondrocytes to adjust to varying extracellular glucose concentrations. However, the function of K(ATP) channels seems to be impaired in chondrocytes from OA cartilage [86]. In addition, there is evidence for altered GLUT1 expression in OA chondrocytes and this may reflect a possible contribution of altered glucose metabolism in the pathogenesis of this disease [25,96]. One likely contributor to this scenario is altered mitochondrial metabolism in OA. Another contributing factor is the low density of chondrocytes within cartilage. Chondrocytes occupy 1–2% of the volume of the tissue in mature adult human articular cartilage, which is approximately one tenth compared to that in other tissues [97].

### 10. Conclusions

The incidence of OA, the age-related inflammatory joint disease characterized by pain and loss of synovial tissue structure and function due to articular cartilage degeneration, is steadily rising across the world as the aging population expands. Therefore health and social care systems across the globe need to prepare for a "tsunami" of OA cases in the next two decades. Although there is a very strong association between age and increasing incidence of OA, the disease itself is not an inevitable consequence of aging; instead, aging increases the risk of OA. This is a very important point and is often overlooked in the scientific literature. A characteristic of OA is deviant behaviour of chondrocytes in diseased articular cartilage [43]. OA chondrocytes resemble terminally differentiated chondrocytes in the growth plate and actively produce pro-inflammatory cytokines and matrix degrading enzymes [43,46]. These catabolic factors result in further cartilage degeneration. Progressive chondrocyte senescence is also characterized by expression of senescence-associated markers, erosion of chondrocyte telomere length and mitochondrial dysfunction due to oxidative damage causing the age related loss of chondrocyte function [98]. In appropriate joint loading and mechanical stresses associated with abnormal loads on the joint considerably increased the production of oxidants and soluble factors that sustain the chondrosenescent phenotype [99]. Chondrosenescence and OA are intimately linked and the premature senescence accounts for age-related decline in chondrocyte function and indicate that mechanically induced oxidative damage plays a role in this process [99]. Poor cartilage repair in older patients is likely to be limited by the inability of older chondrocytes to form new mechanically competent cartilage. Chondrosenescence *in vivo* contributes to the age-related increase in the prevalence of OA and decrease in the efficacy of cartilage repair [44]. Chondrosenescence directly affects the extracellular matrix, resulting in a tissue that is functionally impaired and less able to maintain homeostasis when stressed, resulting in breakdown and loss of the articular cartilage, a classic hallmark of OA [46]. Age-related senescence and loss of muscle and bone mass are also likely to be important as are sarcopenia and increased bone turnover may also contribute to the development of OA [100]. A better understanding of the basic mechanisms underlying senescence and how the process may be modified could provide novel approaches to slow the development of OA and lead to the development of new therapeutic strategies that may delay the onset of chondrocyte senescence or replace senescent cells [101].

### Contributors

Ali Mobasheri: Conceived the concept of chondrosenescence, drafted and submitted the commissioned paper. Csaba Matta:

Drafted two sections, read, edited and approved the submission; made a significant intellectual contribution to the manuscript. Róza Zákány: Drafted one sections, read, edited and approved the submission; made a significant intellectual contribution to the manuscript. Giuseppe Musumeci: Drafted one section, read, edited, and approved the submission; made a significant intellectual contribution to the concept of the manuscript.

## Competing interests

The authors declare no competing interests.

## Funding

A.M. is the coordinator of the D-BOARD Consortium funded by European Commission Framework 7 program (EU FP7; HEALTH.2012.2.4.5–2, project number 305815, Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases). A.M. is also a member of the Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis (Grant Reference: 20194). C.M. is supported by the European Union through a Marie Curie Intra-European Fellowship for career development (project number: 625746; acronym: CHONDRION; FP7-PEOPLE-2013-IEF).

## Provenance and peer review

Commissioned and externally peer reviewed.

## Conflict of interest statement

The authors wrote this paper within the scope of their academic and affiliated research positions. The authors declare no conflict of interests. The authors do not have any commercial relationships that could be construed as biased or inappropriate. AM is the coordinator of the D-BOARD Consortium funded by European Commission Framework 7 program (EU FP7; HEALTH.2012.2.4.5–2, project number 305815, Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases). CM is supported by the European Union through a Marie Curie Intra-European Fellowship for career development (project number 625746; acronym: CHONDRION; FP7-PEOPLE-2013-IEF).

## Acknowledgements

The research leading to these results has received partial funding from the European Union Seventh Framework Programme (FP7/2007–2013, FP7-PEOPLE-2013-IEF) under grant agreement numbers 305815 and 625746. The decision to submit the paper for publication was not influenced by the funding bodies.

## References

[1] Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194–217.
[2] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
[3] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
[4] Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729–40.
[5] Campisi J. Cancer, aging and cellular senescence. In Vivo 2000;14:183–8.
[6] Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614–36.
[7] Campisi J. From cells to organisms: can we learn about aging from cells in culture. Exp Gerontol 2001;36:607–18.
[8] Campisi J. The biology of replicative senescence. Eur J Cancer 1997;33:703–9.
[9] Campisi J. Aging and cancer: the double-edged sword of replicative senescence. J Am Geriatr Soc 1997;45:482–8.
[10] Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010;24:2463–79.
[11] Campisi J. The role of cellular senescence in skin aging. J Investig Dermatol Symp Proc 1998;3:1–5.
[12] Salminen A, Kaarniranta K, Kauppinen A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging (Albany NY) 2012;4:166–75.
[13] Tschopp J. Mitochondria Sovereign of inflammation? Eur J Immunol 2011;41:1196–202.
[14] Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011;469:221–5.
[15] Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci 2012;69:2999–3013.
[16] Franceschi C, Bonafe M. Centenarians as a model for healthy aging. Biochem Soc Trans 2003;31:457–61.
[17] Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007;128:92–105.
[18] Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013;21:16–21.
[19] Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease. Joint Bone Spine 2013;80:568–73.
[20] Lencel P, Magne D. Inflammaging: the driving force in osteoporosis. Med Hypotheses 2011;76:317–21.
[21] Goto M. Inflammaging (inflammation + aging): a driving force for human aging based on an evolutionistic antagonistic pleiotropy theory? Biosci Trends 2008;2:218–30.
[22] Lotz MK, Carames B. Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA. Nat Rev Rheumatol 2011;7:579–87.
[23] Carames B, Taniguchi N, Otsuki S, Blanco FJ, Lotz M. Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis. Arthritis Rheum 2010;62:791–801.
[24] Mobasheri A, Vannucci SJ, Bondy CA, et al. Glucose transport and metabolism in chondrocytes: a key to understanding chondrogenesis, skeletal development and cartilage degradation in osteoarthritis. Histol Histopathol 2002;17:1239–67.
[25] Mobasheri A, Bondy CA, Moley K, et al. Facilitative glucose transporters in articular chondrocytes. Expression, distribution and functional regulation of GLUT isoforms by hypoxia, hypoxia mimetics, growth factors and proinflammatory cytokines. Adv Anat Embryol Cell Biol 2008;200:1 (p following vi, -84).
[26] Archer CW, Francis-West P. The chondrocyte. Int J Biochem Cell Biol 2003;35:401–4.
[27] Henrotin Y, Kurz B. Antioxidant to treat osteoarthritis: dream or reality. Curr Drug Targets 2007;8:347–57.
[28] Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003;11:747–55.
[29] Pfander D, Gelse K. Hypoxia and osteoarthritis: how chondrocytes survive hypoxic environments. Curr Opin Rheumatol 2007;19:457–62.
[30] Lafont JE. Lack of oxygen in articular cartilage: consequences for chondrocyte biology. Int J Exp Pathol 2010;91:99–106.
[31] Imhof H, Sulzbacher I, Grampp S, Czerny C, Youssefzadeh S, Kainberger F. Subchondral bone and cartilage disease: a rediscovered functional unit. Invest Radiol 2000;35:581–8.
[32] Levick JR. Microvascular architecture and exchange in synovial joints. Microcirculation 1995;2:217–33.
[33] Findlay DM. Vascular pathology and osteoarthritis. Rheumatology (Oxford) 2007;46:1763–8.
[34] Henrotin Y, Deby-Dupont G, Deby C, Franchimont P, Emerit I. Active oxygen species, articular inflammation and cartilage damage. EXS 1992;62:308–22.
[35] Hiran TS, Moulton PJ, Hancock JT. In situ detection of superoxide anions within porcine articular cartilage. Br J Biomed Sci 1998;55:199–203.
[36] Hiran TS, Moulton PJ, Hancock JT. Detection of superoxide and NADPH oxidase in porcine articular chondrocytes. Free Radic Biol Med 1997;23:736–43.
[37] Abramson SB. Osteoarthritis and nitric oxide. Osteoarthritis Cartilage 2008;16(Suppl 2):S15–20.
[38] Studer R, Jaffurs D, Stefanovic-Racic M, Robbins PD, Evans CH. Nitric oxide in osteoarthritis. Osteoarthritis Cartilage 1999;7:377–9.
[39] Abramson SB. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 2008;10(Suppl 2):S2.
[40] Abramson SB, Attur M, Amin AR, Clancy R. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Curr Rheumatol Rep 2001;3:535–41.
[41] Moulton PJ, Goldring MB, Hancock JT. NADPH oxidase of chondrocytes contains an isoform of the gp91phox subunit. Biochem J 1998;329(Pt 3):449–51.
[42] Moulton PJ, Hiran TS, Goldring MB, Hancock JT. Detection of protein and mRNA of various components of the NADPH oxidase complex in an immortalized human chondrocyte line. Br J Rheumatol 1997;36:522–9.
[43] van der Kraan PM, van den Berg WB. Osteoarthritis in the context of ageing and evolution. Loss of chondrocyte differentiation block during ageing. Ageing Res Rev 2008;7:106–13.
[44] Martin JA, Buckwalter JA. The role of chondrocyte senescence in the pathogenesis of osteoarthritis and in limiting cartilage repair. J Bone Joint Surg Am 2003;85-A(Suppl 2):106–10.
[45] Buckwalter JA, Mankin HJ. Articular cartilage: degeneration and osteoarthritis, repair, regeneration, and transplantation. Instr Course Lect 1998;47:487–504.

[46] Loeser RF. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthritis Cartilage 2009;17:971–9.

[47] Wyllie AH. Apoptosis: cell death in tissue regulation. J Pathol 1987;153:313–6.

[48] Hockenbery D. Defining apoptosis. Am J Pathol 1995;146:16–9.

[49] Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239–57.

[50] Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989;83:865–75.

[51] Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995;96:1631–8.

[52] Matsumoto S, Muller-Ladner U, Gay RE, Nishioka K, Gay S. Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. J Rheumatol 1996;23:1345–52.

[53] Asahara H, Hasumuna T, Kobata T, et al. Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 1996;81:27–34.

[54] Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996;149:2143–51.

[55] Hasunuma T, Kayagaki N, Asahara H, et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 1997;40:80–6.

[56] Noble BS, Stevens H, Loveridge N, Reeve J. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone 1997;20:273–82.

[57] Walsh DA, Wade M, Mapp PI, Blake DR. Focally regulated endothelial proliferation and cell death in human synovium. Am J Pathol 1998;152:691–702.

[58] Yang C, Li SW, Helminen HJ, Khillan JS, Bao Y, Prockop DJ. Apoptosis of chondrocytes in transgenic mice lacking collagen II. Exp Cell Res 1997;235:370–3.

[59] Hashimoto S, Setareh M, Ochs RL, Lotz M. Fas/Fas ligand expression and induction of apoptosis in chondrocytes. Arthritis Rheum 1997;40:1749–55.

[60] Hashimoto H, Tanaka M, Suda T, et al. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1998;41:657–62.

[61] Blanco FJ, Guitian R, Vazquez-Martul E, de Toro FJ, Galdo F. Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum 1998;41:284–9.

[62] Hashimoto S, Ochs RL, Komiya S, Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum 1998;41:1632–8.

[63] Hashimoto S, Takahashi K, Amiel D, Coutts RD, Lotz M. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis Rheum 1998;41:1266–74.

[64] Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1998;10:263–8.

[65] Hashimoto S, Ochs RL, Rosen F, et al. Chondrocyte-derived apoptotic bodies and calcification of articular cartilage. Proc Natl Acad Sci USA 1998;95:3094–9.

[66] Zamli Z, Sharif M. Chondrocyte apoptosis: a cause or consequence of osteoarthritis. Int J Rheum Dis 2011;14:159–66.

[67] Mistry D, Oue Y, Chambers MG, Kayser MV, Mason RM. Chondrocyte death during murine osteoarthritis. Osteoarthritis Cartilage 2004;12:131–41.

[68] Musumeci G, Loreto C, Carnazza ML, Martinez G. Characterization of apoptosis in articular cartilage derived from the knee joints of patients with osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2011;19:307–13.

[69] Huppertz B, Frank HG, Kaufmann P. The apoptosis cascade—morphological and immunohistochemical methods for its visualization. Anat Embryol (Berl) 1999;200:1–18.

[70] Horton Jr WE, Feng L, Adams C. Chondrocyte apoptosis in development, aging and disease. Matrix Biol 1998;17:107–15.

[71] Roach HI, Aigner T, Kouri JB. Chondroptosis: a variant of apoptotic cell death in chondrocytes. Apoptosis 2004;9:265–77.

[72] Musumeci G, Loreto C, Carnazza ML, Strehin I, Elisseeff J. OA cartilage derived chondrocytes encapsulated in poly(ethylene glycol) diacrylate (PEGDA) for the evaluation of cartilage restoration and apoptosis in an in vitro model. Histol Histopathol 2011;26:1265–78.

[73] Kim HA, Blanco FJ. Cell death and apoptosis in osteoarthritic cartilage. Curr Drug Targets 2007;8:333–45.

[74] Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000;1:11–21.

[75] Matta C, Zakany R. Calcium signalling in chondrogenesis: implications for cartilage repair. Front Biosci (Schol Ed) 2013;5:305–24.

[76] Ureshino RP, Rocha KK, Lopes GS, Bincoletto C, Smaili SS. Calcium signaling alterations, oxidative stress, and autophagy in aging. Antioxid Redox Signal 2014;21:123–19.

[77] Gomez-Pinilla PJ, Pozo MJ, Camello PJ. Aging differentially modifies agonist-evoked mouse detrusor contraction and calcium signals. Age (Dordr) 2011;33:81–8.

[78] Georgeon-Chartier C, Menguy C, Prevot A, Morel JL. Effect of aging on calcium signaling in C57Bl6J mouse cerebral arteries. Pflugers Arch 2013;465:829–38.

[79] Loeser RF, Olex AL, McNulty MA, et al. Microarray analysis reveals age-related differences in gene expression during the development of osteoarthritis in mice. Arthritis Rheum 2012;64:705–17.

[80] Fodor J, Matta C, Juhasz T, et al. Ionotropic purinergic receptor P2X4 is involved in the regulation of chondrogenesis in chicken micromass cell cultures. Cell Calcium 2009;45:421–30.

[81] Matta C, Fodor J, Miosge N, et al. Purinergic signalling is required for calcium oscillations in migratory chondrogenic progenitor cells. Pflugers Arch 2014. Q10

[82] Barrett-Jolley R, Lewis R, Fallman R, Mobasheri A. The emerging chondrocyte channelome. Front Physiol 2010;1:135.

[83] Wu QQ, Chen Q. Mechanoregulation of chondrocyte proliferation, maturation, and hypertrophy: ion-channel dependent transduction of matrix deformation signals. Exp Cell Res 2000;256:383–91.

[84] Randall AD, Booth C, Brown JT. Age-related changes to Na+ channel gating contribute to modified intrinsic neuronal excitability. Neurobiol Aging 2012;33:2715–20.

[85] Bao L, Taskin E, Foster M, et al. Alterations in ventricular K(ATP) channel properties during aging. Aging Cell 2013;12:167–76.

[86] Rufino AT, Rosa SC, Judas F, Mobasheri A, Lopes MC, Mendes AF. Expression and function of K(ATP) channels in normal and osteoarthritic human chondrocytes: possible role in glucose sensing. J Cell Biochem 2013;114:1879–89.

[87] Goyns MH. Genes, telomeres and mammalian ageing. Mech Ageing Dev 2002;123:791–9.

[88] Martin JA, Buckwalter JA. Telomere erosion and senescence in human articular cartilage chondrocytes. J Gerontol A Biol Sci Med Sci 2001;56:B172–9.

[89] Treuhaft PS, MCCarty DJ. Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum 1971;14:475–84. Q11

[90] Schneider N, Mouithys-Mickalad A, Lejeune JP, et al. Oxygen consumption of equine articular chondrocytes: Influence of applied oxygen tension and glucose concentration during culture. Cell Biol Int 2007;31:878–86.

[91] Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev 2001;15:2865–76.

[92] Mobasheri A, Neama G, Bell S, Richardson S, Carter SD. Human articular chondrocytes express three facilitative glucose transporter isoforms: GLUT1, GLUT3 and GLUT9. Cell Biol Int 2002;26:297–300.

[93] Richardson S, Neama G, Phillips T, et al. Molecular characterization and partial cDNA cloning of facilitative glucose transporters expressed in human articular chondrocytes; stimulation of 2-deoxyglucose uptake by IGF-I and elevated MMP-2 secretion by glucose deprivation. Osteoarthritis Cartilage 2003;11:92–101.

[94] Phillips T, Ferraz I, Bell S, Clegg PD, Carter SD, Mobasheri A. Differential regulation of the GLUT1 and GLUT3 glucose transporters by growth factors and pro-inflammatory cytokines in equine articular chondrocytes. Vet J 2005;169:216–22.

[95] Mobasheri A, Gent TC, Nash AI, Womack MD, Moskaluk CA, Barrett-Jolley R. Evidence for functional ATP-sensitive (K(ATP)) potassium channels in human and equine articular chondrocytes. Osteoarthritis Cartilage 2007;15:1–8.

[96] Peansukmanee S, Vaughan-Thomas A, Carter SD, et al. Effects of hypoxia on glucose transport in primary equine chondrocytes in vitro and evidence of reduced GLUT1 gene expression in pathologic cartilage in vivo. J Orthop Res 2009;27:529–35.

[97] Brighton CT, Kitajima T, Hunt RM. Zonal analysis of cytoplasmic components of articular cartilage chondrocytes. Arthritis Rheum 1984;27:1290–9.

[98] Martin JA, Buckwalter JA. Aging, articular cartilage chondrocyte senescence and osteoarthritis. Biogerontology 2002;3:257–64.

[99] Martin JA, Brown TD, Heiner AD, Buckwalter JA. Chondrocyte senescence, joint loading and osteoarthritis. Clin Orthop Relat Res 2004:S96–103.

[100] Loeser RF. Age-related changes in the musculoskeletal system and the development of osteoarthritis. Clin Geriatr Med 2010;26:371–86.

[101] Martin JA, Buckwalter JA. Human chondrocyte senescence and osteoarthritis. Biorheology 2002;39:145–52.